Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
New Strategies in Diagnosis and Treatments for Brain Tumors (Volume...
share announcement

New Strategies in Diagnosis and Treatments for Brain Tumors (Volume II)

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: closed (20 March 2024) | Viewed by 3583

Special Issue Editor

Prof. Dr. Sven Rainer Kantelhardt

E-Mail Website
Guest Editor
Department of Neurosurgery, Vivantes Hospital im Friedrichshain, Landsberger Allee 49, 10249 Berlin, Germany
Interests: glioma; brain tumor; neurosurgery; intraoperative imaging; intraoperative robotics and navigation; personal medicine (for brain tumors)

Special Issue Information

Dear Colleagues,

This Special Issue is the second edition of the Special Issue “New Strategies in Diagnosis and Treatments for Brain Tumors”, available at https://0-www-mdpi-com.brum.beds.ac.uk/journal/cancers/special_issues/NSIDATFBT.

Brain tumors still rank among the most threatening diseases worldwide. The life expectancy of neuro-oncology patients has been stagnating in recent years. The field of scientific neuro-oncology is, however, developing rapidly. New treatment strategies, including non-invasive diagnostics using digital analysis tools and artificial intelligence, enhanced surgical resection techniques and intraoperative imaging, as well as approaches focusing on tumor heterogeneity and molecular characteristics for the specific selection of radio- and chemo-therapies, will soon be employed clinical practice. These approaches carry the potential of shifting the paradigm towards a more individual, personalized treatment and finally improve the prognosis of patients suffering from brain tumors. This Special Issue is dedicated to novel concepts and emerging technologies. It will provide an overview of the state of the art and current trends in diagnostics and therapeutic approaches of brain tumors.

Prof. Dr. Sven Rainer Kantelhardt
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • glioma
  • brain tumor
  • molecular guided therapy
  • personal medicine
  • radiomics
  • digital analysis
  • artificial intelligence
  • intraoperative imaging
  • surgical resection

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

22 pages, 3226 KiB  
Article
The Nitro Group Reshapes the Effects of Pyrido[3,4-g]quinazoline Derivatives on DYRK/CLK Activity and RNA Splicing in Glioblastoma Cells
by Sophia S. Borisevich, Tatiana E. Aksinina, Margarita G. Ilyina, Victoria O. Shender, Ksenia S. Anufrieva, Georgij P. Arapidi, Nadezhda V. Antipova, Fabrice Anizon, Yannick J. Esvan, Francis Giraud, Victor V. Tatarskiy, Pascale Moreau, Mikhail I. Shakhparonov, Marat S. Pavlyukov and Alexander A. Shtil
Cancers 2024, 16(4), 834; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers16040834 - 19 Feb 2024
Viewed by 1105
Abstract
Serine-threonine protein kinases of the DYRK and CLK families regulate a variety of vital cellular functions. In particular, these enzymes phosphorylate proteins involved in pre-mRNA splicing. Targeting splicing with pharmacological DYRK/CLK inhibitors emerged as a promising anticancer strategy. Investigation of the pyrido[3,4-g [...] Read more.
Serine-threonine protein kinases of the DYRK and CLK families regulate a variety of vital cellular functions. In particular, these enzymes phosphorylate proteins involved in pre-mRNA splicing. Targeting splicing with pharmacological DYRK/CLK inhibitors emerged as a promising anticancer strategy. Investigation of the pyrido[3,4-g]quinazoline scaffold led to the discovery of DYRK/CLK binders with differential potency against individual enzyme isoforms. Exploring the structure–activity relationship within this chemotype, we demonstrated that two structurally close compounds, pyrido[3,4-g]quinazoline-2,10-diamine 1 and 10-nitro pyrido[3,4-g]quinazoline-2-amine 2, differentially inhibited DYRK1-4 and CLK1-3 protein kinases in vitro. Unlike compound 1, compound 2 efficiently inhibited DYRK3 and CLK4 isoenzymes at nanomolar concentrations. Quantum chemical calculations, docking and molecular dynamic simulations of complexes of 1 and 2 with DYRK3 and CLK4 identified a dramatic difference in electron donor-acceptor properties critical for preferential interaction of 2 with these targets. Subsequent transcriptome and proteome analyses of patient-derived glioblastoma (GBM) neurospheres treated with 2 revealed that this compound impaired CLK4 interactions with spliceosomal proteins, thereby altering RNA splicing. Importantly, 2 affected the genes that perform critical functions for cancer cells including DNA damage response, p53 signaling and transcription. Altogether, these results provide a mechanistic basis for the therapeutic efficacy of 2 previously demonstrated in in vivo GBM models. Full article
(This article belongs to the Special Issue New Strategies in Diagnosis and Treatments for Brain Tumors (Volume II))
►▼ Show Figures

Figure 1

Review

Jump to: Research, Other

25 pages, 1240 KiB  
Review
Liquid Biopsy for Glioma Using Cell-Free DNA in Cerebrospinal Fluid
by Ryosuke Otsuji, Yutaka Fujioka, Nobuhiro Hata, Daisuke Kuga, Ryusuke Hatae, Yuhei Sangatsuda, Akira Nakamizo, Masahiro Mizoguchi and Koji Yoshimoto
Cancers 2024, 16(5), 1009; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers16051009 - 29 Feb 2024
Cited by 1 | Viewed by 1498
Abstract
Glioma is one of the most common primary central nervous system (CNS) tumors, and its molecular diagnosis is crucial. However, surgical resection or biopsy is risky when the tumor is located deep in the brain or brainstem. In such cases, a minimally invasive [...] Read more.
Glioma is one of the most common primary central nervous system (CNS) tumors, and its molecular diagnosis is crucial. However, surgical resection or biopsy is risky when the tumor is located deep in the brain or brainstem. In such cases, a minimally invasive approach to liquid biopsy is beneficial. Cell-free DNA (cfDNA), which directly reflects tumor-specific genetic changes, has attracted attention as a target for liquid biopsy, and blood-based cfDNA monitoring has been demonstrated for other extra-cranial cancers. However, it is still challenging to fully detect CNS tumors derived from cfDNA in the blood, including gliomas, because of the unique structure of the blood–brain barrier. Alternatively, cerebrospinal fluid (CSF) is an ideal source of cfDNA and is expected to contribute significantly to the liquid biopsy of gliomas. Several successful studies have been conducted to detect tumor-specific genetic alterations in cfDNA from CSF using digital PCR and/or next-generation sequencing. This review summarizes the current status of CSF-based cfDNA-targeted liquid biopsy for gliomas. It highlights how the approaches differ from liquid biopsies of other extra-cranial cancers and discusses the current issues and prospects. Full article
(This article belongs to the Special Issue New Strategies in Diagnosis and Treatments for Brain Tumors (Volume II))
►▼ Show Figures

Figure 1

Other

Jump to: Research, Review

15 pages, 1751 KiB  
Systematic Review
Focused Ultrasound-Enhanced Liquid Biopsy: A Promising Diagnostic Tool for Brain Tumor Patients
by Akke Bakker, Anna E. Ixkes, Hema Venugopal, Mario G. Ries, Nathalie S. M. Lak, Filip Y. F. L. de Vos, Dannis G. van Vuurden and Tom J. Snijders
Cancers 2024, 16(8), 1576; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers16081576 - 19 Apr 2024
Viewed by 591
Abstract
The performance of minimally invasive molecular diagnostic tools in brain tumors, such as liquid biopsy, has so far been limited by the blood–brain barrier (BBB). The BBB hinders the release of brain tumor biomarkers into the bloodstream. The use of focused ultrasound in [...] Read more.
The performance of minimally invasive molecular diagnostic tools in brain tumors, such as liquid biopsy, has so far been limited by the blood–brain barrier (BBB). The BBB hinders the release of brain tumor biomarkers into the bloodstream. The use of focused ultrasound in conjunction with microbubbles has been shown to temporarily open the BBB (FUS-BBBO). This may enhance blood-based tumor biomarker levels. This systematic review provides an overview of the data regarding FUS-BBBO-enhanced liquid biopsy for primary brain tumors. A systematic search was conducted in PubMed and Embase databases with key terms “brain tumors”, “liquid biopsy”, “FUS” and their synonyms, in accordance with PRISMA statement guidelines. Five preclinical and two clinical studies were included. Preclinical studies utilized mouse, rat and porcine glioma models. Biomarker levels were found to be higher in sonicated groups compared to control groups. Both stable and inertial microbubble cavitation increased biomarker levels, whereas only inertial cavitation induced microhemorrhages. In clinical studies involving 14 patients with high-grade brain tumors, biomarker levels were increased after FUS-BBBO with stable cavitation. In conclusion, FUS-BBBO-enhanced liquid biopsy using stable cavitation shows diagnostic potential for primary brain tumors. Further research is imperative before integrating FUS-BBBO for liquid biopsy enhancement into clinical practice. Full article
(This article belongs to the Special Issue New Strategies in Diagnosis and Treatments for Brain Tumors (Volume II))
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop